ClinicalTrials.gg
RecruitingNCT06900270PROTEODACUpdated Mar 28, 2025

Comparative of Plasma Proteomics & Metabolomics in Coronary Artery Disease: Obstructive,Non-Obstructive, & No Lesions

An observational study in Coronary Arterial Disease (CAD), sponsored by University of Sao Paulo General Hospital. Recruiting at 1 site in Brazil. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by University of Sao Paulo General Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
66
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Atherosclerosis with a site in Brazil — 8 open to participants now, 15 under way, 10 of them phase 3. Atherosclerosis · Brazil.

Started
2024
with 4 others
Observational
8 of 54
2 open now
Primary completion
2025-07
later than 0 of 14 live
Registered
47th of 54
by date
Lead sponsor
7 of 54
University of Sao Paulo General Hospital

Among the 54 studies in Atherosclerosis with a site in Brazil, this one is one of 5 that started in 2024, is one of 8 observational ones, reaches primary completion later than 0 of the 14 other live ones, and was the 47th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

8 of the 54 studies in Atherosclerosis with a site in Brazil are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Atherosclerosis with a site in Brazil, or all of them as a file.
02

Study summary

The presence and clinical evolution of coronary atherosclerosis depend on various classic risk factors and biomarkers. However, the search for more specific markers is necessary, especially for individuals with non-obstructive coronary artery disease, lesions \< 50%. In this regard, the field of plasma proteomics could enable the discovery of these novel biological indicators. To evaluate and compare the differences in the proteomic profile among three groups of individuals, namely those without atherosclerotic lesions, those with non-obstructive lesions in coronary flow (\< 50%), and those with obstructive lesions (e 50%), as determined by findings from coronary computed tomography angiography (CCTA) or invasive coronary angiography (ICA). The aim is to assess their relationship with typical clinical events of coronary artery disease (CAD) and detect potential prognostic biomarkers associated with each group. A cross-sectional cohort study involving 66 patients selected and recruited based on CCTA and ICA results obtained at the Heart Institute of the Hospital das Clínicas of the School of Medicine, University of São Paulo (InCor, HC-FMUSP). The patients were divided into the aforementioned three groups, with 22 individuals in each group, and underwent blood collection for biochemical and proteomic analysis, as well as clinical and demographic characterization. The likely differentiation of the proteomic and metabolomic profile among the groups and identification of biological markers for CAD would contribute to the understanding of its pathophysiology and enable a change in clinical decision-making, particularly regarding disease progression prevention and clinical events.

Read the detailed description

INTRODUCTION The presence and clinical evolution of coronary atherosclerosis depend on several classic risk factors, such as age, sex, arterial hypertension, dyslipidemia, diabetes, smoking, family history, and others, including inflammatory markers, coronary calcium, genetic scores, ethnicity, and lifestyle.

However, the markers for disease progression in individual patients remain uncertain; what is currently available is the average progression, not the certainty of real, personalized evolution. This is especially true in individuals with non-obstructive lesions (\<50%). Nevertheless, such patients frequently suffer coronary events, such as myocardial infarction and acute coronary syndrome. Moreover, they represent a large proportion of individuals who experience cardiovascular events.

Thus, the search for more specific prognostic biomarkers continues. The field of plasma proteomics offers a great opportunity for discovering these new markers. Specifically, chemical compounds related to inflammation, platelet function, or endothelial dysfunction may have distinct expression patterns in the aforementioned patients.

With the early detection of coronary artery disease (CAD), ideal and personalized therapies can be initiated. Metabolites can clarify pathogenicity and potential therapeutic targets. A combination of multiple small-molecule metabolites may provide excellent diagnostic value. Therefore, metabolomics, a rapidly expanding field in systems biology, can indicate metabolic alterations in response to disease progression.

For this purpose, plasma, often considered a pool of metabolites, has been an excellent source for determining the metabolic profile in certain diseases. This has also been demonstrated in Coronary Artery Disease (CAD).

Fan et al., in a Chinese cohort, showed statistically significant differences in the metabolism of glycerophospholipids, linoleic acid, purines, and sphingolipids between normal individuals and those with non-obstructive disease. Furthermore, sphingolipids, glycerophospholipids, valine, leucine, isoleucine, primary bile acid biosynthesis, and arginine and proline metabolism differed between obstructive and non-obstructive coronary disease. These differences were detected in 89 differential metabolites.

In the African-American cohort of the Jackson Heart Study, N-acylamides, leucine, and lipid species were associated with the incidence of coronary artery disease.

OBJECTIVE Therefore, the objective of this study is to evaluate differences in the plasma proteomic profile among three groups: Group I, without atherosclerotic lesions; Group II, with non-obstructive lesions (\<50%); and Group III, with obstructive lesions (≥50%), based on findings from coronary computed tomography angiography (CCTA) or invasive coronary angiography (ICA), in order to assess their relationship with typical clinical events of coronary artery disease (CAD) and identify potential biomarkers associated with the prognosis of each group.

Thus, in this pilot project, we hypothesize that plasma proteomic and metabolomic profiles may differ among these three patient groups.

METHODS This is a cross-sectional cohort study with 66 patients from the Heart Institute (InCor) of the Hospital das Clínicas, Faculty of Medicine, University of São Paulo (HC-FMUSP). Patients were selected based on coronary computed tomography angiography (CCTA) or invasive coronary angiography (ICA) performed at InCor HC-FMUSP between 2011 and 2017 and divided into three groups: Group I (n = 22), without atherosclerotic lesions; Group II (n = 22), with non-obstructive lesions (\<50%); and Group III (n = 22), with obstructive lesions (≥50%). Patients will be randomly recruited from the Brazilian Cohort Project on Non-Obstructive Coronary Disease: Lesions with Less Than 50% Obstruction - BARD. This project was previously approved by the Ethics Committee.

Patients will be invited to participate in the study after a selection process based on medical records from the atherosclerosis and chronic coronary disease outpatient clinics at InCor. During a single visit, they will receive detailed information about the study. Upon their agreement and signing of the informed consent form (ICF), they will be included in the study and undergo blood collection and demographic data assessment on the same day.Participation in the study involves risks related to blood collection and the confidentiality of their information. Access to the data will be restricted to study personnel, who are professionally committed to maintaining absolute confidentiality. Participants' names will be replaced by a code, and the data collected for the study will not contain any elements that could potentially allow personal identification.

For sample size calculation, two approaches will be used: the proportion of significant bins-predefined segments in the spectrum after processing metabolomic fingerprinting data-(untargeted analysis) or the proportion of significant proteins (targeted analysis). It is expected that these proportions will be statistically significant, which generally does not exceed 50%. Since this is a pilot project, and there is no prior knowledge of the proportion of significant proteins, Probabilistic Principal Component Analysis (PPCA) was chosen, meaning that an untargeted analysis approach was applied.

For this choice, the following numerical covariates were determined: age, blood glucose, HDL-cholesterol, LDL-cholesterol, total cholesterol, and triglycerides; and categorical covariates: coronary lesion (obstructive lesion, non-obstructive lesion, and no lesion), diabetes mellitus (DM), dyslipidemia (DLP), systemic arterial hypertension (SAH), and smoking. The false discovery rate (FDR) was set at 5%, bins at 200, and the proportion of significant differences at 20%. Thus, the sample size calculated using MetSizeR software version 2.0 was 22 individuals per group (total of 66 participants). The study variables will be presented using descriptive statistics according to variable type (qualitative or quantitative). For qualitative variables, frequencies and percentages will be calculated. For quantitative variables, mean, median, standard deviation, minimum, maximum, first quartile, and third quartile will be presented.

The comparison between two dependent measures will be performed using the non-parametric Wilcoxon test. For comparisons between independent groups, the non-parametric Mann-Whitney test will be used.

The significance level adopted for all hypothesis tests will be 5%. Analyses will be performed using SPSS v.25 for Windows ©.

PROTOCOL During the participant's visit, after obtaining informed consent, demographic characteristics will be recorded (age, sex, risk factors, blood pressure, heart rate, weight, and height), and blood samples will be collected for laboratory biochemical analysis (fasting blood glucose, glycated hemoglobin, troponin I, complete blood count, urea, creatinine, sodium, potassium, high-sensitivity C-reactive protein (hs-CRP), aspartate transaminase, alanine transaminase, total and fractionated bilirubin, alkaline phosphatase, gamma-glutamyl transferase, prothrombin time, total cholesterol and fractions, and triglycerides) and proteomic analysis. The biochemical profile will be analyzed at the Clinical Analysis Laboratory of InCor. Blood samples for the proteomic profile will be collected in standard tubes, coagulated at 4°C for 1 to 2 hours, then warmed to room temperature for 30 minutes before centrifugation (2500g/10 min). The plasma will be stored at -80°C in the freezer of the Vascular Biology Laboratory on the 9th floor of InCor and later sent in a single batch to the Neuroproteomics Laboratory at UNICAMP for analysis. Additionally, metabolomic analysis will be conducted at the Max Feffer Laboratory of Plant Genetics, Department of Genetics, "Luiz de Queiroz" College of Agriculture (ESALQ), University of São Paulo, Piracicaba. Plasma samples will be depleted of the most abundant proteins, and the low-abundance protein fraction will be digested with trypsin. The resulting peptides will then undergo liquid chromatography coupled with mass spectrometry (LC-MS) for proteomic and metabolomic analyses.

DATA ANALYSIS The data obtained by LC-MS will be processed using algorithms for protein identification and quantification, with searches conducted in databases such as the Uniprot Human Proteomic Database (http://www.uniprot.org/). For spectrum processing, the software Progenesis QI for Proteomics 4.0 will be used. The data generated will serve as the basis for protein identification and quantification using the label-free MSE method. In the software, samples will be categorized into the predefined study groups. Proteins will be identified using strict search parameters, requiring at least two unique peptides for protein identification. Differentially expressed proteins between groups will be considered based on a fold change cutoff of 1.5, for both upregulated and downregulated expression. The confidence score will be set at ≥3, and analysis of variance (ANOVA) will be conducted with a p-value threshold of ≤0.05.

03

Conditions studied

  • Coronary Arterial Disease (CAD)

Keywords

  • Atherosclerosis
  • Coronary Circulation
  • Coronary Artery Disease
  • Coronary Occlusion
  • Proteomics
  • Metabolomics
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

  1. Group I: Patients without manifest atherosclerotic disease (no history of angina, previous myocardial infarction, prior revascularization, cerebrovascular disease, or peripheral vascular disease).
  2. Group II: Patients with non-obstructive coronary lesions (\< 50%) detected on coronary computed tomography angiography (CCTA) or invasive coronary angiography (ICA).
  3. Group III: Patients with obstructive coronary lesions (≥ 50%) detected on CCTA or ICA.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Group I: Patients without manifest atherosclerotic disease (no history of angina, previous myocardial infarction, prior revascularization, cerebrovascular disease, or peripheral vascular disease).
  2. Group II: Patients with non-obstructive coronary lesions (\< 50%) detected on coronary computed tomography angiography (CCTA) or invasive coronary angiography (ICA).
  3. Group III: Patients with obstructive coronary lesions (≥ 50%) detected on CCTA or ICA.

Exclusion criteria

Exclusion Criteria:

  1. Patients who refuse to sign the form (ICF);
  2. Individuals with non-atherosclerotic heart disease (such as valvular diseases, cardiomyopathies, or congenital heart diseases);
  3. Severe nephropathy ( \< 30 mL/min/1.73 m² body surface area);
  4. Malignant neoplasms or other chronic diseases with poor prognosis;
  5. Patients with acute coronary syndromes within the last 90 days;
  6. Active smoking.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
66 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group I

    No atherosclerotic lesions

  • Group II

    Non-obstructive coronary lesions (\< 50%)

  • Group III

    Obstructive coronary lesions (≥ 50%)

06

What researchers measure

Primary outcomes

  1. Identification of Differentially Expressed Proteins in Coronary Artery Disease Groups

    Identification of Differentially Expressed Proteins Among Three Groups (No Lesion, Non-Obstructive Lesion, and Obstructive Lesion)

    Time frame: 1 Year

Secondary outcomes

  1. Proteomic Biomarkers and Classic Risk Factors Correlation

    Correlation between proteomic biomarkers and classic risk factors

    Time frame: 1 Year

  2. Association of Identified Proteins with Clinical Events in CAD

    Association of identified proteins with typical clinical events of coronary artery disease

    Time frame: 1 Year

  3. Differential Protein Expression in Relation to Laboratory Biochemical Parameters

    Analysis of differential protein expression in relation to laboratory biochemical parameters.

    Time frame: 1 Year

07

Study locations

1 of 1 sites recruiting
  • Instituto do Coração InCor, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo
    São Paulo, 05403-000, Brazil
    Recruiting
08

References and documents

Publications

  • Finch JP, Wilson T, Lyons L, Phillips H, Beckmann M, Draper J. Spectral binning as an approach to post-acquisition processing of high resolution FIE-MS metabolome fingerprinting data. Metabolomics. 2022 Aug 2;18(8):64. doi: 10.1007/s11306-022-01923-6. PubMed 35917032 ↗
  • Nyamundanda G, Gormley IC, Fan Y, Gallagher WM, Brennan L. MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach. BMC Bioinformatics. 2013 Nov 21;14:338. doi: 10.1186/1471-2105-14-338. PubMed 24261687 ↗
  • Gika HG, Theodoridis GA, Wingate JE, Wilson ID. Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J Proteome Res. 2007 Aug;6(8):3291-303. doi: 10.1021/pr070183p. Epub 2007 Jul 11. PubMed 17625818 ↗
  • Huang Q, Tan Y, Yin P, Ye G, Gao P, Lu X, Wang H, Xu G. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res. 2013 Aug 15;73(16):4992-5002. doi: 10.1158/0008-5472.CAN-13-0308. Epub 2013 Jul 1. PubMed 23824744 ↗
  • Silva-Costa LC, Smith BJ, Carlson PT, Souza GHMF, Martins-de-Souza D. Human Blood Plasma Investigation Employing 2D UPLC-UDMSE Data-Independent Acquisition Proteomics. Methods Mol Biol. 2021;2259:153-165. doi: 10.1007/978-1-0716-1178-4_9. PubMed 33687713 ↗
  • Cruz DE, Tahir UA, Hu J, Ngo D, Chen ZZ, Robbins JM, Katz D, Balasubramanian R, Peterson B, Deng S, Benson MD, Shi X, Dailey L, Gao Y, Correa A, Wang TJ, Clish CB, Rexrode KM, Wilson JG, Gerszten RE. Metabolomic Analysis of Coronary Heart Disease in an African American Cohort From the Jackson Heart Study. JAMA Cardiol. 2022 Feb 1;7(2):184-194. doi: 10.1001/jamacardio.2021.4925. PubMed 34851361 ↗
  • Fan Y, Li Y, Chen Y, Zhao YJ, Liu LW, Li J, Wang SL, Alolga RN, Yin Y, Wang XM, Zhao DS, Shen JH, Meng FQ, Zhou X, Xu H, He GP, Lai MD, Li P, Zhu W, Qi LW. Comprehensive Metabolomic Characterization of Coronary Artery Diseases. J Am Coll Cardiol. 2016 Sep 20;68(12):1281-93. doi: 10.1016/j.jacc.2016.06.044. PubMed 27634119 ↗
  • Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. PubMed 19212411 ↗
  • Cheng ML, Wang CH, Shiao MS, Liu MH, Huang YY, Huang CY, Mao CT, Lin JF, Ho HY, Yang NI. Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. J Am Coll Cardiol. 2015 Apr 21;65(15):1509-20. doi: 10.1016/j.jacc.2015.02.018. PubMed 25881932 ↗
  • Savaryn JP, Catherman AD, Thomas PM, Abecassis MM, Kelleher NL. The emergence of top-down proteomics in clinical research. Genome Med. 2013 Jun 27;5(6):53. doi: 10.1186/gm457. eCollection 2013. PubMed 23806018 ↗
  • Ferrannini E, Manca ML, Ferrannini G, Andreotti F, Andreini D, Latini R, Magnoni M, Williams SA, Maseri A, Maggioni AP. Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans. Front Cardiovasc Med. 2022 Feb 4;8:790289. doi: 10.3389/fcvm.2021.790289. eCollection 2021. PubMed 35187107 ↗
  • Ostgren CJ, Soderberg S, Festin K, Angeras O, Bergstrom G, Blomberg A, Brandberg J, Cederlund K, Eliasson M, Engstrom G, Erlinge D, Fagman E, Hagstrom E, Lind L, Mannila M, Nilsson U, Oldgren J, Ostenfeld E, Persson A, Persson J, Persson M, Rosengren A, Sundstrom J, Swahn E, Engvall JE, Jernberg T. Systematic Coronary Risk Evaluation estimated risk and prevalent subclinical atherosclerosis in coronary and carotid arteries: A population-based cohort analysis from the Swedish Cardiopulmonary Bioimage Study. Eur J Prev Cardiol. 2021 Apr 23;28(3):250-259. doi: 10.1177/2047487320909300. Epub 2020 Mar 3. PubMed 33891684 ↗
  • Fernandez-Friera L, Penalvo JL, Fernandez-Ortiz A, Ibanez B, Lopez-Melgar B, Laclaustra M, Oliva B, Mocoroa A, Mendiguren J, Martinez de Vega V, Garcia L, Molina J, Sanchez-Gonzalez J, Guzman G, Alonso-Farto JC, Guallar E, Civeira F, Sillesen H, Pocock S, Ordovas JM, Sanz G, Jimenez-Borreguero LJ, Fuster V. Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation. 2015 Jun 16;131(24):2104-13. doi: 10.1161/CIRCULATIONAHA.114.014310. Epub 2015 Apr 16. PubMed 25882487 ↗
  • Ahmadi A, Argulian E, Leipsic J, Newby DE, Narula J. From Subclinical Atherosclerosis to Plaque Progression and Acute Coronary Events: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Sep 24;74(12):1608-1617. doi: 10.1016/j.jacc.2019.08.012. PubMed 31537271 ↗
  • Maddox TM, Stanislawski MA, Grunwald GK, Bradley SM, Ho PM, Tsai TT, Patel MR, Sandhu A, Valle J, Magid DJ, Leon B, Bhatt DL, Fihn SD, Rumsfeld JS. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA. 2014 Nov 5;312(17):1754-63. doi: 10.1001/jama.2014.14681. PubMed 25369489 ↗
  • Makarovic Z, Makarovic S, Bilic-Curcic I, Mihaljevic I, Mlinarevic D. NONOBSTRUCTIVE CORONARY ARTERY DISEASE - CLINICAL RELEVANCE, DIAGNOSIS, MANAGEMENT AND PROPOSAL OF NEW PATHOPHYSIOLOGICAL CLASSIFICATION. Acta Clin Croat. 2018 Sep;57(3):528-541. doi: 10.20471/acc.2018.57.03.17. PubMed 31168187 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Jul 2025, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Mar 28, 2025
StartActual
Aug 1, 2024
Primary completionEst.
Jul 1, 2025
CompletionEst.
Feb 1, 2026
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06900270
Responsible party
Sponsor
First posted
Mar 28, 2025
Start date
Aug 1, 2024
Primary completion
Jul 1, 2025 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
Mar 28, 2025

Study contacts

Vinícius Quintão MD
Contact
vinicius.quintao@hc.fm.usp.br
55 11 2661-5795
Protasio da Luz PhD
principal investigator · Instituto do Coração InCor, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion